Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Sarafoglou K, Lorentz CP, Otten N, Oetting WS, Grebe SKG. Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening. Newborn screening (NBS) identifies the majority of classical [salt‐wasting (SW) and simple‐virilizing (SV)] cases of congenital adrenal hyperplasia (CAH) due to 21 α‐hydroxylase (21 α‐OHase) during the first days of life. Diagnosis of classical CAH is confirmed by follow‐up serum 17‐hydroxyprogesterone and/or the adrenocorticotropin stimulation test; however, neither test definitively distinguishes between the classical subtypes. After confirmation, all newborns are started on hydrocortisone (glucocorticoid) and fludrocortisone (mineralocorticoid) treatment. While initiating fludrocortisone treatment in classical CAH patients, independent of subtype and before SW signs or symptoms occur, prevents a life‐threatening SW crisis, it may later complicate distinguishing between the classical subtypes. Genotype–phenotype correlations in 21 α‐OHase deficiency are excellent; however, molecular testing is not a regular part of the diagnostic workup. Molecular testing on 39 patients (25 identified by NBS) with an already established diagnosis of CAH identified 11 SW patients (8 identified by NBS) whose mutations suggested further biochemical and clinical reassessment of their subtype. Overall, SW accounted for 57.6% of our classical CAH patients, below the generally accepted figure that >75% of classical CAH are comprised of the SW form. In the era of NBS, molecular testing is a valuable supplemental tool identifying patients who may benefit from reassessment of their salt‐retaining ability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 4×
“However, after NBS identification and confirmatory testing to establish the diagnosis of classical CAH, all newborns are started on fludrocortisone per consensus recommendations (4).”
BackgroundMethodResultInfluentialCongenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
Krone, N., Braun, A., Roscher, A. A., Knorr, D., & Schwarz, H. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6441 · Cited by 397
Wedell, A. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1145 · Cited by 370
Tusie-Luna, M. T., Traktman, P., & White, P. C. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45304-x · Cited by 254 · cited 1×
“1683G>T mutation, which causes a substitution of valine by leucine at codon 281, allowing for approximately 30–60% activity of the 21OHlase enzyme (19), was found in five patients with NC including two in whom sequencing of the CYP21A2 gene failed to identify a second mutation (both patients had elevated stimulated 17…”
BackgroundMutation in the CYP21B gene (Ile-172-Asn) causes steroid 21-hydroxylase deficiency
Amor, M., Parker, K. L., Globerman, H., New, M. I., & White, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.5.1600 · Cited by 251
Higashi, Y., Hiromasa, T., Tanae, A., Miki, T., Nakura, J., Kondo, T., Ohura, T., Ogawa, E., Nakayama, K., & Fujii-Kuriyama, Y. (1991) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123433 · Cited by 201
Forest, M. G. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh047 · Cited by 200 · cited 1×
“6% of our classical 21α-OHase deficiency patients, below the generally accepted figure that >75% of classical CAH is comprised of the SW form (25, 26).”
BackgroundFinkielstain, G. P., Chen, W., Mehta, S. P., Fujimura, F. K., Hanna, R. M., Van Ryzin, C., McDonnell, N. B., & Merke, D. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0319 · Cited by 192 · cited 1×
“655A/C>G single nucleotide substitution that creates an aberrant intron 2 splice acceptor site and the 30-kb deletion were the most frequent mutation in SW-CAH patients (Table 2) (8, 10).”
BackgroundTusie-Luna, M.-T., Speiser, P. W., Dumic, M., New, M. I., & White, P. C. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-5-685 · Cited by 183 · cited 1×
“89C>T mutation has been associated with NC if the allele aberration is based on a single base substitution (20) and an intermediate SV/NC phenotype if it is part of a larger gene deletion/conversion event with a hybrid junction site before intron 2 (21, 22).”
Background
Cited by
de Carvalho, D. F., Miranda, M. C., Gomes, L. G., Madureira, G., Marcondes, J. A. M., Billerbeck, A. E. C., Rodrigues, A. S., Presti, P. F., Kuperman, H., Damiani, D., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0171 · Cited by 75
Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia
Sarafoglou, K., Banks, K., Gaviglio, A., Hietala, A., McCann, M., & Thomas, W. (2012) · PEDIATRICS · doi:10.1542/peds.2012-1219 · Cited by 69
Self-citationCases of congenital adrenal hyperplasia missed by newborn screening in Minnesota
Sarafoglou, K., Banks, K., Kyllo, J., Pittock, S., & Thomas, W. (2012) · JAMA · doi:10.1001/jama.2012.5281 · Cited by 62
Self-citationLai, F., Srinivasan, S., & Wiley, V. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6030063 · Cited by 32
“Variant analysis has been reported to be able to further discriminate SVCAH from SWCAH [53]; however, so far the literature suggests that variant analysis has only been used as an adjunct for screening [36].”
BackgroundResult
Metadata
- Authors
- Sarafoglou, K., Lorentz, C. P., Otten, N., Oetting, W. S., & Grebe, S. K. G.
- Venue
- Clinical Genetics
- Publisher
- Wiley
- Published
- 2011-06-03
- Volume
- 82
- Issue
- 1
- Pages
- 64-70
- ISSN
- 0009-9163 (ISSN-L)
- 1399-0004
- OpenAlex
- W2101943800
- Cited by
- 16
- References
- 16
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening. https://app.cochat.ai/papers/10.1111/j.1399-0004.2011.01694.x
- The paper
- Sarafoglou, K., Lorentz, C. P., Otten, N., Oetting, W. S., & Grebe, S. K. G. (2012). Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening. Clinical Genetics. https://doi.org/10.1111/j.1399-0004.2011.01694.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.